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The genetic etiology of prostate cancer, the most common form of male cancer in western countries, is complex and the interplay of
disease genes with environmental factors is far from being understood. Studies on somatic mitochondrial DNA (mtDNA) mutations
have become an important aspect of cancer research because these mutations might have functional consequences and/or might serve
as biosensors for tumor detection and progression. We sequenced the entire mitochondrial genome (16,569 bp) from 30 prospectively
collected pairs of macrodissected cancerous and benign cells from prostate cancer patients and compared their genetic variability. Given
recent concerns regarding the authenticity of newly discovered mtDNA mutations, we implemented a high-quality procedure for
mtDNA whole-genome sequencing. In addition, the mitochondrial genes MT-CO2, MT-CO3, MT-ATP6, and MT-ND6 were sequenced
in further 35 paired samples from prostate cancer patients. We identified a total of 41 somatic mutations in 22 out of 30 patients:
the majority of these mutations have not previously been observed in the human phylogeny. The presence of somatic mutations in
transfer RNAs (tRNAs) was found to be associated with elevated PSA levels (14.255 5.44 versus 7.155 4.32 ng/ml; p¼ 0.004). The level
and degree of heteroplasmy increased with increasing tumor activity. In summary, somatic mutations in the mitochondrial genome are
frequent events in prostate cancer. Mutations mapping to mitochondrial tRNAs, ribosomal RNAs, and protein coding genes might
impair processes that occur within the mitochondrial compartment (e.g., transcription, RNA processing, and translation) and might
finally affect oxidative phosphorylation.Introduction
Prostate cancer is the most frequent cancer among men in
the United States1 and the third most common cancer in
the European Union.2 Although genome-wide association
studies identified several risk loci for prostate cancer on
autosomal genes,3–7 extensive analyses on the roles of
mitochondrial DNA (mtDNA) mutations are missing.
Mitochondria have been implicated in the process of
carcinogenesis because of their vital role in energy produc-
tion8 and apoptosis.9 The mitochondrial genome exhibits
a highmutation rate10 and accumulates somaticmutations
and deletions in tumor tissue.11–14 The evolution of the
human mitochondrial genome is characterized by the
emergence of haplogroups, clusters of evolutionary closely
related pedigrees that are defined by certain polymor-
phisms.15 These haplogroup-specific polymorphisms are
widely neutral, and presumable associations of these evo-
lutionary informative polymorphisms to cancer risk have
led to ongoing discussion.16 The haplogroup affiliation
was found to have no influence on prostate cancer in
a European17 as well as in an Asian population18 but
was reported to be a risk factor in a North American
population.19
Another feature of mtDNA is the occurrence of hetero-
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different nucleotide composition in a single cell, tissue,
or individual. Identification of low levels of heteroplasmy
are thought to allow an early identification and moni-
toring of neoplastic progression to malignancy.
Up to now, the influence of mtDNA on the origin and
progression of prostate cancer has not been understood.
Although many studies seem to support an active role
of mtDNA in prostate tumorigenesis,20–22 there are con-
cerns regarding the data quality, interpretation, and even
the experimental design, which undermine the original
claims. A critical reassessment of reported somatic muta-
tions in cancers employing phylogenetic algorithms re-
vealed that many of these investigations were affected by
erroneous data and that the high frequency of mutations
could be attributed to artifacts instead of real somatic
events.23
The aim of the present study was to clarify the role of
somatic mtDNAmutations in prostate cancer by analyzing
frequency and nature of somatic mtDNA mutations and
their suitability for monitoring malignant transformation,
tumor progression, and metastasis. We sequenced the
entire mitochondrial genome in macrodissected prostate
cancer tissue with varying Gleason scores and distant
benign cells by using a rigorous high-quality sequencing
strategy. With this strategy, low levels of heteroplasmyand Clinical Pharmacology, InnsbruckMedical University, 6020 Innsbruck,
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can be identified, which may allow the identification of an
early stage of tumorigenesis and the monitoring of further
progression to malignancy.Material and Methods
Patient Data
Tissue samples were prospectively collected over a time frame of
18 months starting in January 2009. Patients aged 18 or older,
who had signed an informed consent, were consecutively
included in the study. Patients with a prostate carcinoma that
had been treated with chemotherapy or radiotherapy before pros-
tatectomy were excluded. Because we expected a higher mutation
rate in patients with advanced stages of prostate cancer, we
selected a higher proportion of patients with Gleason score 8
and 9, followed by those with score 7 and less with low scores.
The following clinical parameters were collected: age; prostate-
specific antigen (PSA) level at diagnosis; development of a tumor
relapse during follow-up; Gleason score of the radical prostatec-
tomy diagnosis; TNM-stadium (including extraprostatic exten-
sion24); and Epstein criteria (significant versus insignificant).25
On average, the patients were followed for 24 months after tumor
diagnosis (interquartile range: 8–41 months). This study was
approved by the ethics committee of the Innsbruck Medical
University (study code UN3426).Tissue Samples and DNA Extraction
DNA from prostate cancer was extracted from 65 patients (primary
screen: n ¼ 30; targeted screen: n ¼ 35) who underwent a radical
prostatectomy (Table S1 available online). A uropathologist deter-
mined benign and predominantly malign regions on HE-stained
slides from frozen sections. Because prostate cancer shows hetero-
geneous growth patterns with various amounts of benign glands
between tumor cells, areas with the highest possible density
of cancer were selected. The chosen tissue was additionally
confirmed to be either cancerous or tumor-free by immunohisto-
chemistry (benign: positive expression of the basal cell marker
p63; cancer: no expression of p63).26 Quantitative cell number
analysis of the macrodissected areas was performed by the combi-
nation of an image acquisition and data management module
(HistoFAXS, TissueGnostics, Vienna) plus an analysis module for
immunohistochemical staining (HistoQuest). This system auto-
matically acquires immunohistochemically stained sections with
nuclear counterstaining and performs quantitative analysis via
algorithms, which allow the identification of the total cell number
(with Hematoxylin as marker) and specific cell numbers (with the
specific antibodies E-Cadherin and p63 as markers). Thereby, the
total number and percentage of epithelial prostate cancer cells,
benign epithelial prostate cells, and nonepithelial cells (stromal/
endothelial/inflammatory/blood cells) could be calculated.
In several patients, cancer from the prostate gland had already
invaded the seminal vesicles. In one of these patients we extracted
DNA from seminal vesicle-invasive cancer formations in addition
to the intraprostatic tumor. Per patient, three frozen sections corre-
sponding to the selected area on theHE-stained slideswere used for
macrodissection. Regions with predominantly malignant and
purely benign cells were each encircled with a sapphire cutter,
and theDNA extraction buffer was applied directly onto the frozen
section. After a few minutes, the buffers retaining the dissolved
tissue of the corresponding regions were gathered with a pipetteThe Americanand fused into one reaction tube. DNA was extracted with
a BioRobot EZ1 advanced Workstation with the EZ1 DNA tissue
kit (QIAGEN, Hilden, Germany) and quantified with a NanoDrop
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA).Amplification and Sequencing of the Entire
Mitochondrial Genome
The entire mitochondrial genome from 30 patients was sequenced
separately for both benign and cancerous tissue samples. Amplifi-
cation was done in two overlapping fragments of approximately
9 kb each according to the strategy published by Gonder et al.27
withminor modifications (fragments A and B; Table S2). Fragment
B could not be amplified in samples harboring a mutation on
m.C10670T, so we used an alternative primer pair in these cases
(region 9754 to 3557, fragment B2, Table S2). The DNAwas ampli-
fied in a total reaction volume of 100 ml, containing about 560 ng
(fragment A) or 400 ng (fragment B) of DNA, 2 ml of Herculase II
Fusion DNA Polymerase (Stratagene, La Jolla, CA), 20 ml of
53PCR reaction buffer, 250 mM each dNTP (Stratagene), and
0.25 mM each primer. The amplification reaction was conducted
on a 96-well thermal cycler (Bio-Rad Laboratories GmbH, Munich,
Germany). The reaction cocktails were heated to 95C (2min) and
then put through 10 touch-down reaction cycles: 95C for 20 s,
69C–0.5C/cycle for 20 s, and 72C for 4 min 30 s, followed by
40 amplification cycles with an annealing temperature of 64C
and a final extension phase at 72C for 10 min. For better cycling
performance, PCR mastermixes were split into two 50 ml reactions
and fused again after purification with the QiaVac (QIAquick Mul-
tiwell PCR Purification Kit; QIAGEN). Each sample was sequenced
with 96 primers (48 for each fragment) that were arrayed on
a primer master-plate similar to Fendt et al.28 with mostly pub-
lished27–34 and several newly designed primers (Table S2). For cycle
sequencing, 2 ml of purified PCR product were combined with the
sequencing master mix (containing 1 ml BigDye Terminator v1.1
Cycle Sequencing RR mix [Applied Biosystems, AB, Foster City,
CA], 3 ml Sequencing Buffer [AB], 0.3 mM primer, and distilled
water up to 10 ml) and cycled (after a first denaturation step of
96C, 1 min) for 25 cycles of 10 s at 96C, 5 s at 50C, and
4 min at 60C. Purification of cycle-sequencing products with
Sephadex (GE Healthcare) was according to the procedure
described in Brandsta¨tter et al.30 Electrophoretic separation was
carried out on an ABI3130xl capillary sequencer with POP-7 and
a 36 cm capillary array.Amplification and Sequencing of Selected Regions
After the primary screen, mitochondrial genes that were hit by
somatic mutations several times were selectively targeted in
further 35 patients. Threemitochondrial fragments were amplified
and sequenced: Fragment C1 (amplified with primers F7249 and
R9509; sequenced with primers F7249, R7773, F7619, F7956,
R8082, F8129) spanned 1830 bp, including MT-TS1 (MIM
590080), MT-TD (MIM 590015), MT-CO2 (MIM 516040), and
MT-TK (MIM 590060). Fragment C2 (amplified with primers
F8355 and R10259; sequenced with primers F8355, F8559,
F8708, F9123, R9383, F9330, F9507, F9770, F9892) spanned
1928 bp, including MT-ATP6 (MIM 516060), MT-CO3 (MIM
516050), and MT-TG (MIM 590035). Fragment D (amplified with
primers F13920 and R14976; sequenced with primers F13920,
F14189, F14311, F14490) spanned 1098 bp, including MT-ND6
(MIM 516006) and MT-TE (MIM 590025). The reaction cocktails
were heated to 95C (2 min) and then put through 30Journal of Human Genetics 87, 802–812, December 10, 2010 803
amplification cycles: 95C for 20 s, 62C for 20 s, and 72C for
1 min, followed by a final extension phase at 72C for 3 min.
40 ng of DNA were amplified in a total reaction volume of 20 ml,
containing 0.2 ml of Herculase II Fusion DNA Polymerase, 4 ml of
53PCR reaction buffer, 250 mM each dNTP, and 0.25 mM each
primer. Post-PCR treatment and cycle sequencing was performed
as described above.Sequence Evaluation, Quality Management,
and Haplogroup Determination
Sequence electropherograms were aligned to the revised Cam-
bridge Reference Sequence (rCRS; NC_01292035) with Sequencher
(v4.9, GeneCodes, Ann Arbor, MI). A nucleotide position was
considered heteroplasmic if a secondary peak of more than about
10% of the height of the primary peak was present. This needed to
be confirmedwith at least one forward and one reverse sequencing
reaction or two different forward reactions. In the case of homo-
polymeric cytosine tracts, we determined the number of cytosines
by counting the number of ‘‘dominant Cs.’’ Point heteroplasmic
mixtures were characterized by comparing the heights of the
two contributing peaks36 (Figure 1).
Every mtDNA genome was evaluated independently by two
mtDNA technicians and validated by a senior mtDNA scien-
tist with the mtDNA management software eCOMPAGT.37,38
eCOMPAGT enables an error-free postlaboratory data handling of
human mtDNA profiles, because mtDNA profiles can be imported
from different sequence evaluation programs, compared between
evaluations, and connected to phenotype data for genetic associa-
tion analyses. In addition, somatic mutations, i.e., differences
between benign and cancerous mtDNA profiles from one patient,
were automatically extractedwith eCOMPAGT. ThemtDNAhaplo-
types were affiliated to haplogroups with HaploGrep39 based on
patterns of haplogroup-specificorhaplogroup-associatedpolymor-
phisms as summarized in PhyloTree.15 For quality assurance and
in order to exclude contamination as potential source for the
observed heteroplasmies, entire mtDNA profiles were generated
from four lab technicians, who were involved in sample handling
and genotyping.Bioinformatic and Statistical Analyses
The potential functional impact of all identified nonsynonymous
mutations was analyzed with tools from the GenEpi Toolbox,40
namely Polyphen,41 SIFT,42 and PMUT.43 The predictions were
combined as reported in Table S3 to form a three-staged rating
of the functional relevance of each mutation. For analyzing the
impact of somatic transfer RNA (tRNA) mutations, we consulted
Mamit-tRNA.44
Expectations between two unrelated variables were tested for
equality via a Mann-Whitney U-test. Pearson’s chi-square test
was used to assess whether paired observations on two categorical
variables were independent of each other. Where sample sizes
were small, Fisher’s exact test was used. Linear regression was
applied to analyze the relationship between several independent
variables and the PSA value as dependent variable. Statistical anal-
yses were performed with SPSS 17.0 (SPSS Inc., Chicago, IL).Results
We sequenced the entire mitochondrial genome (16,569
bp) in benign and cancerous tissue samples from 30804 The American Journal of Human Genetics 87, 802–812, Decembpatients with prostate cancer and four lab technicians
(Figure 2 and Table S4). The mtDNA sequences can be
accessed via GenBank (HM625678–HM625711). The hap-
logroup distribution was equivalent to the haplogroup
structure of a local population sample of 273 healthy Aus-
trians30 (p ¼ 0.498). The profiles obtained from 35 further
patients sequenced for selected regions are summarized in
Table S5.
In the primary entire mtDNA genome screen of
30 patients, we detected 41 somatic mutations in the
cancerous tissue as point or length heteroplasmies on 39
nucleotide positions in 22 patients (Table S6 and Figure 3).
In order to ensure that the somatic mutations in the
cancerous tissue were definitely not derived from germline
mutations, we additionally collected blood samples from
10 patients who exhibited a somatic tumor mutation
(patients PCA003, PCA009, PCA012, PCA014, PCA018,
PCA020, PCA022, PCA023, PCA025, and PCA027) and
sequenced their entire mitochondrial genome from white
blood cells. All of these blood samples showed the identical
mtDNA profile as the benign tissue samples and were
free of the somatic tumor mutations observed in the
respective cancerous tissue.
In the secondary targeted scan in 35 patients, we identi-
fied five additional somatic tumor mutations on different
positions in three patients (Table S6). Thus, the targeted
sequencing did not support our hypothesis that these
specific genes were more susceptible to somatic mutations
than other parts of the mitochondrial genome.
Somatic Mutations in the Control Region
The control region (16024–16569; 1–576) presented a low
degree of somatic mutations. Three point heteroplasmic
mutations on m.G16047R, m.G16390R, and m.G513R
were observed; interestingly, the latter two were observed
only in the seminal vesicle from invasive cancer forma-
tions in patient PCA015, but not in the same patient’s
intraprostatic tumor tissue. m.G16390R was also present
in the benign tissue from this patient (at low level,
~15%), but m.G513R was exclusively seen in the malig-
nant seminal vesicle.
Somatic Mutations in Ribosomal RNAs
In total, seven somatic mutations within ribosomal RNA
genes (MT-RNR1 [MIM 561000] and MT-RNR2 [MIM
561010]) were observed in 30 mitochondrial genomes.
As the major components of mitochondrial ribosomes,
ribosomal RNAs play essential roles in mitochondrial
protein synthesis.45 None of the somatic MT-RNR2 muta-
tions has previously been observed in the human phy-
logeny overseeing data from 5140 individuals,46 thus sug-
gesting a high pathological character of these mutations.
Two mutations are especially interesting. The somatic
deletion at position m.2150_2151delTA is located in the
GTPase-associated center, which is involved in binding of
elongation factor EFG, which catalyzes the translocation
of tRNAs on the ribosome;47 the mutation might thuser 10, 2010
Figure 1. HE Staining and Immunohistochemical Expression of p63 in Prostate Tissue Sections
(A) 40-fold magnification of frozen sections showing HE staining of benign (A1 and A3, left side) and prostate cancer (A3, right side)
tissue and immunohistochemical staining for the basal cell marker p63 (brown) with positive expression in benign (A2 and A4, left
side) and negative expression in cancer glands (A4, right side).
(B) 40-fold magnification of paraffin slides (from formalin-fixed tissue adjacent to the frozen material) showing HE staining of benign
(B1) and prostate cancer (B3) tissue and immunohistochemical staining for p63 in benign cells (B2) and negative expression in cancer
glands (B4).
(C) 400-fold magnification of selected cut-outs of the slides shown in (B).
(D) Example of a heteroplasmic mutation in MT-CO3 in the cancerous tissue of one sample, which was not present in the normal
tissue.
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Figure 2. Phylogenetic Tree Representing the Benign Profiles of 30 Prostate Cancer Patients and Four Lab Technicians
The sequences are stored in GenBank (accession numbers HM625678–HM625711, corresponding to PCA001–PCA030 and Lab001–
Lab004). The position of the rCRS is indicated for reading off sequence motifs. Mutations are transitions unless a base is explicitly
indicated. The prefix ‘‘@’’ designates reversions, whereas suffixes indicate transversions (to A, G, C, or T), indels (.1, d), and heteroplas-
mies (R, Y). The variation in number of Cs at nucleotide position 16193, 309, and 315 was not included in the phylogeny; detailed infor-
mation regarding each mtDNA is available in Table S4. Point heteroplasmic mutations that were observed in benign tissue samples are
highlighted in turquoise.
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Figure 3. Distribution of All Observed Somatic
Mutations over the Mitochondrial Genome
Transfer RNAs are shaded in light blue. The loca-
tion of the PCR fragments for the primary screen
of entire mtDNA genomes (fragments A and B)
and the secondary, targeted screen (fragments C
and D) are indicated in the inner circle of the
mtDNA.delay protein synthesis by interfering with mitochondrial
tRNA translocation. The mutation m.T879Y disrupts a
pseudoknot-interaction within MT-RNR1, which might
result in an interference with mitochondrial protein syn-
thesis and function. m.T879Y was also observed in an
independent study on cancer samples.48
Interestingly, we observed point heteroplasmy
(m.T1443Y) in the benign tissue of sample PCA026, which
was not present in the corresponding tumor tissue. We
repeated the entire analysis with freshly extracted DNA,
but obtained an identical result. We observed a slight
tendency to higher Gleason scores in tumors with a
somatic ribosomal RNA mutation (p ¼ 0.043).
Somatic Mutations in Transfer RNAs
Within 30 entire mtDNA genomes, we observed five
somatic mutations mapping within tRNA genes with pos-
sibly dramatic consequences (Figure 4). m.T10436Y was
located within the anticodon of MT-TR (MIM 590005)
and changes the arginine anticodon to a glutamine anti-
codon, most probably resulting in a misincorporation of
arginine at glutamine codons. m.G1623R was located in
the D-stem ofMT-TV (MIM 590105) and could be expected
to disrupt a Watson-Crick base pair with a possible impact
on the D-loop, thus disturbing the global conformation
of the tRNA. Length heteroplasmy was detected at
m.7471_7472insC in MT-TS1 in the prostate carcinoma
and malignant seminal vesicle of patient PCA015, with
the heteroplasmy being more pronounced in the tumorThe American Journal of Humanof the seminal vesicle. m.7471_7472insC
was already found in gastric carcinoma.49
Interestingly, the presence of somatic tRNA
mutations was strongly associated with
the occurrence of somatic control region
mutations (p ¼ 0.018). Patients with a
somatic tRNA mutation had a significantly
higher PSA value at diagnosis than patients
without a somatic tRNAmutation (14.255
5.44 versus 7.15 5 4.32 ng/ml; p ¼ 0.004)
(Figure 5).
Somatic Mutations in Protein-Coding
Regions
The mutation m.G8184R was found in the
benign tissue as well as in the tumor tissue
from the prostate gland and the seminal
vesicle from patient PCA015: the amount
of the mutated nucleotide increased fromthe benign tissue (15%) to prostate tumor (30%) to seminal
vesicle tumor (40%), which supports the hypothesis that
the proportion of mutated mtDNA molecules increases
with malignancy. A similar observation was made with
the MT-ATP6 mutation m.C870Y: whereas the benign
tissue exhibited 40% of the mutated nucleotide, in the
cancerous tissue the mutated predominated over the
wild-type nucleotide. The observation of three further
mutations on m.T8736Y, m.T8772Y, and m.T9116Y in
the relatively small region of MT-ATP6 (680 bp) suggested
that MT-ATP6 could be especially susceptible to somatic
mutations. Therefore, we genotyped further 35 prostate
cancer patients specifically in MT-ATP6, but we found
only one additional mutation (m.G9157R).
Linear Regression Analysis
The presence of a somatic tRNAmutation was significantly
associated with PSA levels after controlling for age and
Gleason score (p ¼ 0.014) (Table 1). The influence of the
Gleason score on PSA levels was borderline significant
(p ¼ 0.055).Discussion
Although many tumors have been found to contain
somatic mtDNA mutations, little is known about whether
these mutations alter the signature of a tumor cell.
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Figure 4. Location of Somatic tRNA Mutations in the Secondary Structure of the tRNAsMT-ATP6 transcripts was found to be decreased in tumor
samples when compared to their paired normal samples,
suggesting that mitochondrial gene expression is altered
in prostate cancer.50 In addition, highly metastatic cells
showed reduced activity of NADH dehydrogenase, and
these defects were shown to result from pathogenic muta-
tions in the mtDNA.51 Another recent study20,52 intro-
duced an mtDNA mutation into human prostate cancer
cells, which substantially increased tumor growth in the
bone, supporting the concept that mtDNA mutations
enhance prostate cancer bone metastasis. Clearly, mtDNA
copy number increases during prostate cancer develop-
ment53 and could thus further increase the effects of path-
ogenic mutations. Indeed, it was found that in somatic
cancer sequences, mtDNA genes show relaxed negative
selection relative to germline, with considerably higher
cancer missense mutation rates, suggesting that tumors
select for mutations located at highly functional positions
within the mitochondrial genome.54
The majority (55.8%) of somatic mutations that we
found in our sample have so far not been observed in
the human phylogeny, and further 30.2% of somatic
mutations occurred at frequencies below 1% in a database
of 5140 entire human genomes.46 Notably, 14% of the808 The American Journal of Human Genetics 87, 802–812, Decembsomatic mutations are well known to be associated with
various mitochondrial diseases (Table S6), thus again
emphasizing their deleterious signature. Interestingly,
however, none of the mutations described in Petros
et al.,20 who focused on somatic MT-COI mutations
(MIM 516030), were found in our study population. This
suggests that a screening for specific mutations will not
be effective but rather sequencing of selected mitochon-
drial regions might result in a mutation spectrum useful
for prognosis. This line is supported by the different muta-
tion spectrum we have found in the second part (targeted
screen) of our study.
The most intriguing observation from our mutation
screenwas the association between the presence of somatic
tRNA mutations and PSA levels at diagnosis. PSA is pro-
duced in the prostatic glands inside the prostate and
functions in the liquidification of the seminal fluid. The
basement membrane surrounding the normal prostate
gland prevents PSA from entering the blood. When the
tissue and basement membranes are injured, this barrier
is decreased. Transfer RNAs are key molecules in transla-
tion of genetic information from mRNA into proteins.
The mitochondrial tRNA machinery consists of only 22
different tRNAs, thereby lacking tRNA isoacceptor variantser 10, 2010
Table 1. Linear Regression on PSA Levels
Variable Coefficient SE p Value
Age at diagnosis 0.286 0.117 0.021
Gleason score 1.089 0.543 0.055
Somatic mutation in tRNA 5.778 2.203 0.014
The outcome variable was the PSA level; the influence of somatic mutations in
tRNAs was evaluated by adjusting also for age and Gleason score.
Figure 5. Difference in PSA at Diagnosis between Patients with
and without Somatic tRNA Mutationsfor most mitochondrial mRNA codons, with the exception
of serine and leucine.55 Given this low redundancy, it is
not surprising that a growing number of human diseases
are found to be correlated to point mutations inmitochon-
drial tRNA genes. Mutations in tRNAs can impair the pro-
cessing of genes, the aminoacylation, and the protein
synthesis. The accumulation of nonfunctional mitochon-
drial proteins could affect tissue integrity, resulting in
increased leaking of PSA into the blood circulation, which
could then lead to elevated PSA levels. Alternatively, cancer
cells disrupt the blood-prostate barrier, thereby causing
leakage of PSA.
In general, all tRNA mutations and at least two of the
described ribosomal RNA mutations might have a con-
verging negative effect on protein synthesis in mitochon-
dria by interfering with the translation machinery. The
expected result from such interference in protein synthesis
is a lack of mitochondrial function, in particular a reduc-
tion or inhibition of oxidative phosphorylation.
Another intriguing observation was that somatic muta-
tions in tRNAs were associated with somatic mutations in
the noncoding control region. The control region is the
main regulatory region; it contains stem-loop hairpins
forming mitochondrial origins of replication (OL). Addi-
tionally, tRNA genes also form OL-like structures that
initiate mitochondrial replication and thus function as
alternative OLs.56 It was shown that pathogenic mutations
in tRNA genes, especially within anticodon loops, increase
the tRNA’s capacities to form secondary structures resem-
bling mitochondrial OL, which might then invoke bidirec-
tional replication.56 This could subsequently cause sec-
ondary mutations in other genomic regions such as the
mitochondrial control region.
Our study cannot unambiguously answer the question
whethermutations were the cause for ormerely a reflection
of genomic instability. An excess of amino acid changes
relative to the rate of silent changes indicates positiveThe Americanselection; fewer missense mutations indicate negative
selection.54 Indeed, there were exactly twice as many
somatic missense mutations as synonymous mutations
in our sample, hinting to a highly relaxed negative selec-
tion in cancer cells relative to germline. The somatic muta-
tions found in the HVS-II C-stretch of the control region
suggest genome vulnerability; however, the plethora of
nonsynonymous mutations in genes contributing prod-
ucts to the electron transport process predicts a negative
effect on metabolic processes. Moreover, mutations in
mitochondrial tRNAs will very probably severely interfere
with mitochondrial protein synthesis. The occurrence of
somatic cancer mutations in highly conserved residues
therefore suggests thatmutations impairingmitochondrial
function may confer a mitogenic advantage in the chang-
ing cancer microenvironment.
The investigation of the patient with a tumor in the
prostate gland that had invaded the seminal vesicle sheds
further light on the question of whether the processes of
somatic mtDNA mutation accumulation and increase of
tumor progression were independent events. Indeed, the
invasive tumor tissue showed two additional somatic
mutations that were not present in the primary tumor,
and in addition the proportion of the mutant nucleotide
was higher in the invasive tumor compared to the pri-
mary tumor. Another interesting observation was that all
patients with heteroplasmic point mutations in benign
tissue samples had a Gleason score of 9; however, given
the high percentage of Gleason 9 tumors in our sample
of 30 entire mtDNA genome patients, the chance of
randomly observing all benign heteroplasmic point muta-
tions in Gleason 9 tumors was 20.1%. So this could either
be a perchance observation or it could hint to a pre-exist-
ing condition of low-level heteroplasmy, which either
initiated carcinogenesis or induced tumor proliferation,
higher aggressiveness, and invasive growth pattern,
because the level of heteroplasmy was considerably more
pronounced in the tumor tissue compared to the benign
tissue. We can exclude contamination of the benign tissue
with tumor cells, because the DNA was extracted from
different and distant frozen sections for benign and
cancerous tissue samples and the selected benign tissue
was confirmed to be tumor free by immunohistochemistry.
The selection of tumors for our study was intentionally
biased toward high-grade tumors because we expected
mutations to occur mainly in these advanced stages.
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selected about three times more patients with Gleason
score 8 to 9 with an underrepresentation of those with
score 5 to 6. This is clearly not representative of patients
with prostate cancer who are treated by radical prostatec-
tomy. However, this selection would not have an effect
on the observation that somatic mtDNA mutations are
common in advanced stages of prostate cancer.
The possibility to detect heteroplasmy by PCR and
consecutive Sanger sequencing strongly depends on
the amplification strategy57 and on the overall quality of
the electropherograms. Low-level heteroplasmy (mixtures
with minor components below 20%) can be spotted only
in sequences with low background noise.36 However,
Sanger sequencing allows semiquantitative estimations
only on the actual amounts within the mixture. Depend-
ing on the position and direction of the sequencing primer
(forward or reverse) and on the sequence neighborhood
of the heteroplasmic position, the proportion of the over-
lapping basecalls on one position can vary dramatically
(this phenomenon can be seen, for example, in Figure 1).
Our approach to tackle the problem was to average the
mixture ratio over all available sequence reads on a given
heteroplasmic position. A very comprehensive overview
of the capacities of next-generation sequencing to detect
and quantify mtDNA heteroplasmy is provided by a recent
study of Li and coworkers.58 The authors found that by
following stringent quality control measures for avoiding
false positive resulting from sequencing error, hetero-
plasmy could be reliably detected down to a level of 10%
of the minor component. Therefore, next-generation
sequencing technologies can provide new insights into
genome-wide aspects of mtDNA heteroplasmy.
In summary, our study has several strengths: (1) it targets
the entire mitochondrial genome in cancer and benign
tissue from the same patient with a superior sequencing
strategy that has stringent quality assurance procedures;
(2) the prospective character of the study enabled the eval-
uation of the incidence of a tumor relapse depending on
the occurrence of somatic mutations; and (3) the paired
design of our study targeting both benign and carcino-
genic tissue within the same person increases the power
of our study, because the detection probability of cancer-
related mutations is higher in paired samples than case-
control studies involving people without prostate cancer.
The small sample size (n ¼ 30) and the lack of a functional
characterization of the detected somatic mutations could
be considered as limitations of our study. However,
with the increasing implementation of next-generation
sequencing technologies, it should be possible to screen
larger well-characterized prostate cancer samples for
somatic mutations and to validate the association of
somatic tRNA mutations with PSA levels.Supplemental Data
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